Rounds Report: Crispr Rallied While The FDA Approved Lumivascular

We have a passion for keeping things simple. - Charlie Munger

Trading Analytics

Welcome to this edition of Integrated BioSci Rounds Report for May 24, 2018. As usual, we��ll elucidate notable trading analytics for the day, recent insider transactions, and interesting market developments. Without further ado, let��s take an overall assessment of the bioscience space. As follows, the iShares of NASDAQ Biotechnology Index (NASDAQ:IBB) traded up by $0.53 (+0.50%) at $107.25. Moreover, the SPDR S&P Biotech (NYSE:XBI) exchanged hands $0.28 higher at $92.44 (for +0.30% gains). As witnessed, investors were trading with a positive sentiment for the day. Regardless of the daily inclination, there are substantial prospects in the bioscience sector: one that delivers hope for patients while rewarding supporters with substantial wealth in the long haul.

Figure 1: Notable BioSci movers (Source: Yahoo Finance)

Moving to specific equities, Crispr Therapeutics (NASDAQ:CRSP) won the highlight spot of the day. Accordingly, the stock moved $5.89 higher at $69.57 for over 9.1% profits. Headquartered in Zug Switzerland, Crispr is an innovator of gene-editing to potentially treat rare and life-threatening diseases. With strong underlying fundamentals, as reflective in the early preclinical data and other ongoing corporate developments, the stock procured over 255% for subscribers of Integrated BioSci Investing.

Notably, there are two gene-editing systems (zinc finger nuclease and CRISPR/Cas9). While both are excellent mechanisms of tinkering the genes to deliver novel therapeutics, we are most interested in the former (which is employed by Crispr). The main reason is that bacteria have employed CRISPR for millions of years and thereby fine-tuned it directly via evolution. By harnessing the power of CRISPR/Cas9, it��s highly favorable that the lead molecule (CTX-001) will deliver strong results for the beta-thalassemia franchise. Reflective of a company gearing up for its next growth phase, Crispr has been streamlining its management team. Going forward, we expect more fortunes for other gene editing and gene therapy innovators as featured in the Specialty Report.

Figure 2: CRISPR/Cas9 (Source: Crispr Therapeutics)

Bioscience Catalysts

On May 23, 2018, Avinger (NASDAQ:AVGR), announced that the FDA approved the 510(NYSE:K) for its next-generation Pantheris Lumivascular atherectomy system. This is an unprecedented image-guided device that removes the plaque inside the artery (atherectomy), indicated for the treatment of the common condition, peripheral artery disease (��PAD��). In response, the shares of the $10.55M (micro-cap stock) shot up over 73%.

Of note, Lumivascular is the only technology with real-time imaging inside the artery for highly effective catheters treatment of PAD. The aforesaid condition is estimated to occur in more than 21M Americans by 2020. With the approval, this grower is positioned to profit from the highly prevalent condition. Thrilled with the aforesaid development, the Present and CEO (Jeff Soinski) enthused,

We are excited to introduce the next generation Pantheris to our network of physicians here in the US. After extensive testing by our R&D and operations teams, physician design validation, and successful initial case experience in Europe across a variety of different lesion types, we believe this next generation device will significantly improve the user experience in terms of reliability, efficiency, and ease of use across a spectrum of clinical situations.

The approval delivers hopes to countless American suffering from PAD - a condition that tends to occur with heart disease, obesity, and diabetes. And, it��s prevalence is growing as we��re writing this report. Asides from the medical view, this milestone delivers increasing wealth for the shareholders. Hence, it��s not a bad idea to initiate a small pilot position in this company to potentially profit from the further upsides.

Final Remarks

In all, the bioscience market continued to amass further profits for investors. Many companies under our coverage rallied. The most notable is Crispr Therapeutics. As one of the leaders in gene-based therapy, the company revealed the stellar early preclinical data. The future clinical binary for the beta-thalassemia franchise is highly likely to be positive. The company is also streamlining its management. Last but not least, the FDA approval of Lumivascular to deliver hopes for patients suffering from PAD while rewarding shareholders with substantial gains.

Author��s Notes: We��re honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (��IBI��) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 328%, 148%, 264%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Of note, there is an IBI version of this article that is a higher-level intelligence with extensive details, in which we published in advanced and exclusively for our subscribers. And, we invite you to subscribe to our marketplace now to lock in the current price and save money for the future.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Our research articles are best used as starting points in your own due diligence. We are not registered investment advisors and our articles are not construed as professional investment advice. Many new research are requests from private investors of our services (Integrated BioSci Investing and Dr. Tran BioSci), who either paid or donated us to support our efforts (in assisting investors and bioscience innovators to deliver hopes to patients). That aside, I like to inform readers of Seeking Alpha's recent policy change, in which the company implemented the paywall (not only to our articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.